---
title: "Wolverine World Wide, Inc. Stock 12‑Month Price Target Cut to $23, Implies 48% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286476447.md"
description: "Wolverine World Wide, Inc.'s stock price target has been reduced from $23.3 to $23, indicating a potential upside of 48% based on the May 13 closing price. The consensus rating remains a \"Buy\" from 11 analysts, with 6 Buys and 5 Holds. Forecasts for the stock range from $18 to $29 per share."
datetime: "2026-05-14T22:20:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286476447.md)
  - [en](https://longbridge.com/en/news/286476447.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286476447.md)
---

# Wolverine World Wide, Inc. Stock 12‑Month Price Target Cut to $23, Implies 48% Upside

-   According to estimates from 10 analysts, Wolverine World Wide, Inc. stock's average price target has fallen from $23.3 to $23, with forecasts ranging from $18 to $29 per share
-   Based on the May 13 closing price, the updated target implies approximately 48% potential upside
-   Consensus rating remains at “Buy” across 11 covering analysts, with 6 Buys, 5 Holds and 0 Sells

Explore more price target data and ratings for Wolverine World Wide, Inc. on the , and track all previous and future analyst recommendations for Wolverine World Wide, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [WWW.US](https://longbridge.com/en/quote/WWW.US.md)

## Related News & Research

- [Telsey Advisory Sticks to Their Hold Rating for Wolverine World Wide (WWW)](https://longbridge.com/en/news/286435467.md)
- [Where Wolverine World Wide Stands With Analysts](https://longbridge.com/en/news/271792339.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [Earnings Beat: Odfjell Drilling Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286515920.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)